4//SEC Filing
Anacor Pharmaceuticals, Inc. 4
Accession 0000950103-15-004569
CIK 0001411158operating
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 7:35 PM ET
Size
13.3 KB
Accession
0000950103-15-004569
Insider Transaction Report
Form 4
Bell Graeme
Executive VP and CFO
Transactions
- Award
Common Stock
2015-06-01+6,006→ 6,006 total - Award
Performance Restricted Stock Units
2015-06-01+8,008→ 8,008 total→ Common Stock (8,008 underlying) - Award
Stock Option (right to buy)
2015-06-01+28,793→ 28,793 totalExercise: $69.34Exp: 2025-06-01→ Common Stock (28,793 underlying) - Award
Performance Restricted Stock Units
2015-06-01+4,004→ 4,004 total→ Common Stock (4,004 underlying)
Footnotes (4)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is June 1, 2015.
- [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date is June 1, 2015.
- [F3]Represents performance restricted stock units granted to the Reporting Person. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. In the event that the volume-weighted average price of the Issuer's Common Stock equals or exceeds (i) $80.00 per share for 30 consecutive trading days prior to January 1, 2016 or (ii) $100.00 per share for 30 consecutive trading days prior to January 1, 2017, the shares subject to the award shall vest in two equal annual installments following the date on which the condition specified in clause (i) or (ii) is met.
- [F4]Represents performance restricted stock units granted to the Reporting Person. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. In the event that the volume-weighted average price of the Issuer's Common Stock equals or exceeds (i) $80.00 per share for 30 consecutive trading days prior to January 1, 2017, 50% of the shares subject to the award shall vest in two equal annual installments following the date on which the condition specified in this clause (i) is met, and (ii) $100.00 per share for 30 consecutive trading days prior to January 1, 2017, the remaining 50% of the shares subject to the award shall vest in two equal annual installments following the date on which the condition specified in this clause (ii) is met.
Documents
Issuer
Anacor Pharmaceuticals, Inc.
CIK 0001411158
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001411158
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 7:35 PM ET
- Size
- 13.3 KB